Background Inhalation of the bacterial peptide N-formyl-methionyl-leucyl-phenylalanine (FMLP) produces bronchoconstriction in normal subjects. FMLP thus has a putative role as a mediator of bronchoconstriction associated with bacterial bronchial infection. Methods The effects ofFMLP inhalation were examined in ten subjects with a history of chronic bronchitis and ten age matched control subjects. Each subject inhaled FMLP doses from 0 025 to 0-8
Background Inhalation of the bacterial peptide N-formyl-methionyl-leucyl-phenylalanine (FMLP) produces bronchoconstriction in normal subjects. FMLP thus has a putative role as a mediator of bronchoconstriction associated with bacterial bronchial infection. Methods The effects ofFMLP inhalation were examined in ten subjects with a history of chronic bronchitis and ten age matched control subjects. Each bronchitis was 0'06 pmol (95% confidence interval 0-015-0-26), which was significantly lower than that in the control subjects (0-21 pmol (0 02-1P9)). PD20 FMLP in the patients with chronic bronchitis but not age matched controls (p = 0 35) was lower than that found previously in young normal subjects (0 35 pmol (0-07- [1] [2] [3] [4] [5] [6] [7] [8] . The return to 95% baseline FEV, occurred after 86(10) minutes in subjects with chronic bronchitis and in 81(23) minutes in their age matched controls, in both cases being much slower than that seen in young subjects (29(9) Thus there may be differences in the response to FMLP between normal young subjects and older subjects with chronic bronchitis, who are most susceptible to the development of respiratory failure during bacterial bronchial infection. The purpose of this study was to determine the effects of inhaled FMLP on subjects with chronic bronchitis and to compare changes in airway function and haematological changes after FMLP with age matched controls.
Methods
Ten subjects with a history of cough and sputum production consistent with the diagnosis of chronic bronchitis and ten age matched controls without chronic bronchitis were selected for the study. Subjects were recruited from patients referred for resection of lung cancer, except for three control subjects (one asymptomatic, one with atypical chest pain and one waiting for hip surgery). The control group consisted of six former smokers without chronic bronchitis and four subjects who had never smoked. Subjects in both groups were aged between 60 and 70 years and none had a history of asthma or recent respiratory infection. The presence or absence of chronic bronchitis and smoking history were determined by clinical interview before lung function testing and bronchial provocation. No subject was taking inhaled or oral corticosteroid or theophylline.
Each subject performed a histamine challenge using the method of Yan.'6 The provocative dose ofhistamine needed to cause a 20% fall in FEV, (PD20 histamine) was always greater than 2 ,mol. The histamine challenge was performed on a separate day before the FMLP challenge. Subjects in the chronic bronchitis group, still smoking at the time of entry, were not challenged with FMLP or histamine until they had ceased smoking for seven days. The protocol was approved by the institutional ethics committee of Concord Hospital. All subjects gave informed consent for participation. [1] [2] [3] [4] [5] [6] 4umol rather than 0-8 /umol.
ANALYSIS
Group comparisons were made between the subjects with chronic bronchitis, the age matched controls and previous data from normal young subjects." In examining values for PD20 FMLP from normal young subjects, those which were greater than 0-8 ,umol were censored to the maximum dose given in this study (0-8 imol). Log PD20 FMLP and time to return to baseline were compared by the Wilcoxon rank sum test.
Comparison of PD20 histamine after FMLP and DMSO was made on log transformed data by the Wilcoxon test for paired differences. White cell and differential leucocyte counts were compared by using the Student's t test. Correlations were determined by nonparametric regression. Data are presented as mean (SE) or geometric mean (95% confidence limits) as appropriate.
Results
The mean age of the patients with chronic bronchitis was 66 years (range 62-70 years), compared with 65 years (range 63-69 years) in the elderly control subjects. The mean age of the young control subjects was 35 years (range 28-42 years). The mean (SE) baseline FEVy value in the patients with chronic bronchitis was 72(2 1)% of predicted, and in the elderly controls 82(5-3)% of predicted (p > 0-1). Mean (SE) baseline FEV1 in the young control subjects was 94(4-1)% of predicted, significantly greater than that in patients with chronic bronchitis but not elderly pontrols. Patients with chronic bronchitis had smoked a mean total of 59(3) pack years. The six former smokers in the age matched control group had smoked a mean of 55 pack years with a mean non-smoking interval of seven years (range 2-15 years). Baseline histamine responsiveness was similar in the two older groups. Geometric mean PD20 histamine in the patients with chronic bronchitis was 6-9 imol (4-7-10 2 ILP in patients with chronic bronchitis RESPONSIVENESS ng normal subjects as 2-5 doubling Repeat histamine challenge in one subject with ,(95% confidence interval of the dif-chronic bronchitis was not possible after 1-7-3-2); that between patients with FMLP because FEV, was too low 60 minutes )ronchitis and their age matched con-after the final FMLP dose. Geometric mean s 1-7 doubling dilutions (029-3 2). PD20 histamine in the nine subjects evaluable is no significant difference between the was 6-9 yimol (4-7-10-2 imol) at baseline, 4 6 jumol (1-3-18-0 pmol) after FMLP inhalation and 5-7 ,mol (3-0-10-9 ,umol) after DMSO. the subjects with chronic bron-effect of age as older subjects recover from 1-0)% of the baseline value, the histamine induced bronchoconstriction at a ing 5-4%. PD20 histamine after rate similar to that of younger subjects (Peters, ed within one doubling dilution unpublished observations). value in all subjects. There was One explanation for this prolonged duration total or differential white cell of effect would be that metabolism of FMLP slows with age. In view of its distribution in the lung,23 FMLP hydrolysis in bronchial mucosa is likely to be via the enzyme neutral endopeptidase as in neutrophils.24 Inhibition of neutral chial infection is the most endopeptidase enhances the effect of FMLP on itant of acute respiratory failure cholinergic neurotransmission in rabbit airway chronic airflow limitation' 2 and in vitro25 though we found a pronounced if morbidity and mortality. We reduction in the bronchoconstrictor response Ijects with chronic bronchitis to FMLP inhalation after inhibition of neutral cted to lower doses of inhaled endopeptidase invivo.26Neutral endopeptidase covery from FMLP induced activity does not decline with age and, if ction was delayed in the older anything, serum activity is increased modestly ctive of the presence of chronic in subjects with chronic airflow limitation.27
The prolonged response to FMLP in the older lo difference in PD20 FMLP, subjects cannot be explained by changes in bronchoconstriction or in the neutral endopeptidase. FMLP inhalation did not produce changes in neutrophil or monocyte counts in venous blood in either group of the magnitude that we had seen in normal subjects.29 There was also a total absence of facial flushing in both older groups after FMLP inhalation whereas flushing is seen in over 75% of young subjects,""293' always occurring after the first FMLP dose and always associated with marked neutropenia.29
Transient neutropenia after FMLP inhalation probably reflects synchronous activation of circulating neutrophils and temporary sequestration in the microcirculation. We have usually given a single inhalation of 0-4jumol FMLP to young subjects after finding variability in the neutrophil responses to incremental doses of FMLP (0 1, 0-5, 1 Mmol).3`Nevertheless, all young normal subjects inhaling the incremental doses of FMLP had either a transient neutropenia or neutrophilia or both; in this study even the five older control subjects who had a dose of FMLP equivalent to that given to young normal subjects had a minimal neutrophil leucocytosis following FMLP.
The leucocyte response to FMLP may require access of FMLP to the circulation. Neutrophils from well older subjects have higher resting intracellular calcium concentrations and the response to a variety of stimuli including FMLP is slightly reduced.3233 A final possibility is that the neutrophils of older subjects, behave in a similar way to those of younger subjects but less in synchrony so that flushing and profound neutropenia which may require synchronous neutrophil activation adherence are not seen. Although the neutropenic response was absent in the older subjects, bronchoconstriction was similar in the older control subjects to that in the younger normal subjects and was increased in subjects with chronic bronchitis. The role that leucocytes play in FMLP induced bronchoconstriction is clearly not linked directly to the development of neutropenia in either age group.
In this study, subjects with chronic bronchitis showed greater sensitivity to the effects of inhaled FMLP and older subjects showed delayed recovery from FMLP induced bronchoconstriction in comparison with young subjects. The combination of disease related increased sensitivity and age related slowing of recovery would place an older patient with chronic bronchitis at special risk ofthe effects of FMLP and related formyl peptides produced by bacteria during bacterial bronchial infection.
